[go: up one dir, main page]

EA201590166A1 - Комбинированная терапия для лечения рассеянного склероза - Google Patents

Комбинированная терапия для лечения рассеянного склероза

Info

Publication number
EA201590166A1
EA201590166A1 EA201590166A EA201590166A EA201590166A1 EA 201590166 A1 EA201590166 A1 EA 201590166A1 EA 201590166 A EA201590166 A EA 201590166A EA 201590166 A EA201590166 A EA 201590166A EA 201590166 A1 EA201590166 A1 EA 201590166A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
teriflunomide
fingolimod
agent selected
dimethyl fumarate
Prior art date
Application number
EA201590166A
Other languages
English (en)
Other versions
EA201590166A8 (ru
Inventor
Тайс Тервей
Рональд Рупп
Педер М. Андерсен
Original Assignee
Форвард Фарма А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Форвард Фарма А/С filed Critical Форвард Фарма А/С
Publication of EA201590166A1 publication Critical patent/EA201590166A1/ru
Publication of EA201590166A8 publication Critical patent/EA201590166A8/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к способу лечения PC у пациента-человека, нуждающегося в таком лечении, включающему введение указанному пациенту терапевтической комбинации в единичной лекарственной форме для перорального применения (например, таблетке или капсуле) диметилфумарата и одного агента, выбранного из терифлуномида (или его пролекарства лефлуномида), финголимода и лахинимода. Указанная комбинация эффективнее отдельных агентов и/или имеет меньше побочных эффектов и лучшую переносимость, чем агенты по отдельности, и/или может вводиться с меньшей частотой. Кроме того, настоящее изобретение направлено на фармацевтическую композицию, подходящую для перорального лечения рассеянного склероза, состоящую из диметилфумарата и одного агента, выбранного из терифлуномида, финголимода и лахинимода в качестве активных ингредиентов, и одного или более фармацевтически приемлемых наполнителей.
EA201590166A 2012-08-03 2013-08-02 Комбинированная терапия для лечения рассеянного склероза EA201590166A8 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12179232.9A EP2692343A1 (en) 2012-08-03 2012-08-03 Combination therapy for treatment of multiple sclerosis
US201261712008P 2012-10-10 2012-10-10
EP12187939.9A EP2692344A1 (en) 2012-08-03 2012-10-10 Combination therapy for treatment of Multiple sclerosis
PCT/EP2013/066285 WO2014020156A1 (en) 2012-08-03 2013-08-02 Combination therapy for treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
EA201590166A1 true EA201590166A1 (ru) 2015-06-30
EA201590166A8 EA201590166A8 (ru) 2015-10-30

Family

ID=47008405

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590166A EA201590166A8 (ru) 2012-08-03 2013-08-02 Комбинированная терапия для лечения рассеянного склероза

Country Status (21)

Country Link
US (2) US20150164849A1 (ru)
EP (4) EP2692343A1 (ru)
JP (2) JP2015523407A (ru)
KR (3) KR20150040338A (ru)
CN (3) CN107669668A (ru)
AU (3) AU2013298517A1 (ru)
CA (2) CA3107367A1 (ru)
DK (1) DK2879672T3 (ru)
EA (1) EA201590166A8 (ru)
ES (1) ES2674947T3 (ru)
HK (1) HK1211210A1 (ru)
HR (1) HRP20180939T1 (ru)
HU (1) HUE038382T2 (ru)
LT (1) LT2879672T (ru)
PL (1) PL2879672T3 (ru)
PT (1) PT2879672T (ru)
RS (1) RS57567B1 (ru)
SI (1) SI2879672T1 (ru)
SM (1) SMT201800380T1 (ru)
TR (1) TR201808859T4 (ru)
WO (1) WO2014020156A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022177A2 (en) 2008-08-19 2010-02-25 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
JP2015526477A (ja) 2012-08-22 2015-09-10 ゼノポート，インコーポレイティド メチル水素フマレートの経口剤形およびそのプロドラッグ
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
MA40982A (fr) 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
TR201820976A2 (tr) * 2018-12-28 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇ngoli̇mod ve bi̇r spazmoli̇ti̇k i̇çeren farmasöti̇k kombi̇nasyonlar
EP4230655A3 (en) * 2019-09-11 2023-11-01 Novartis AG Treatment of rms by switching therapy
EP4117785A4 (en) 2020-03-13 2024-04-17 Marc J. Simard METHODS OF TREATMENT OF MULTIPLE SCLEROSIS
CN116672325B (zh) * 2023-06-06 2024-09-03 哈尔滨工业大学 一种包覆中性粒细胞膜的聚芬戈莫德纳米前药的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006307A2 (en) 2005-07-07 2007-01-18 Aditech Pharma Ab Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
US20080299196A1 (en) * 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
PT2379063E (pt) * 2009-01-09 2013-05-03 Forward Pharma As Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão
ME02317B (me) 2010-02-12 2016-06-20 Biogen Ma Inc Neuroprotekcija kod demijelinizacijskih bolesti
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate

Also Published As

Publication number Publication date
AU2013298517A1 (en) 2015-03-05
HRP20180939T1 (hr) 2018-12-14
US20150164849A1 (en) 2015-06-18
CN113288891A (zh) 2021-08-24
EA201590166A8 (ru) 2015-10-30
EP2879672B1 (en) 2018-04-11
CN107669668A (zh) 2018-02-09
AU2018201801B2 (en) 2019-11-21
ES2674947T3 (es) 2018-07-05
CN104684553A (zh) 2015-06-03
KR20200142597A (ko) 2020-12-22
AU2020201290B2 (en) 2021-08-19
EP3398595A1 (en) 2018-11-07
PL2879672T3 (pl) 2018-10-31
HK1211210A1 (zh) 2016-05-20
JP2018150375A (ja) 2018-09-27
AU2018201801A1 (en) 2018-04-05
JP2015523407A (ja) 2015-08-13
EP2879672A1 (en) 2015-06-10
RS57567B1 (sr) 2018-10-31
CA2880742A1 (en) 2014-02-06
EP2692343A1 (en) 2014-02-05
PT2879672T (pt) 2018-07-03
CA3107367A1 (en) 2014-02-06
LT2879672T (lt) 2018-07-10
SI2879672T1 (sl) 2018-10-30
US20190091190A1 (en) 2019-03-28
KR20210147083A (ko) 2021-12-06
WO2014020156A1 (en) 2014-02-06
TR201808859T4 (tr) 2018-07-23
DK2879672T3 (en) 2018-07-30
EP2692344A1 (en) 2014-02-05
HUE038382T2 (hu) 2018-10-29
KR20150040338A (ko) 2015-04-14
SMT201800380T1 (it) 2018-09-13
CA2880742C (en) 2021-03-16
AU2020201290A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
MX2019012884A (es) Terapia de combinacion.
SA520411119B1 (ar) تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
BRPI0707235B1 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
IN2015DN00376A (ru)
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
NZ617397A (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
BR112015009504A2 (pt) inibidores de rock
JP2016505050A5 (ru)
EA201390345A1 (ru) Терапевтическое болеутоляющее средство
MX2013003523A (es) Composicion farmaceutica de dosis baja.
RU2020108631A (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты
EA201892706A1 (ru) Комбинированная терапия для лечения рассеянного склероза
MX2018013477A (es) Acidos carboxilicos para tratar/prevenir una enfermedad de la piel.
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.